ArticlebioRxiv : the preprint server for biology2025
Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Radiosensitizers are compounds given concurrently with radiotherapy to enhance the killing of cancer cells while sparing healthy tissue. Radiosensitization research has involved a diverse range of therapeutic agents. In the present study, we aimed to investigate international trends in the development of radiosensitizers across the most common cancer types. Methods: A bibliometric analysis was performed of the field of radiosensitizer research from 1956 to 2024. Individual author impacts and trends, collaborations between and productivity of countries, and themes/keywords were analyzed. Results: Our search yielded 12,690 results. The most highly represented countries were the United States of America, China, and Germany. Radiosensitizer studies for breast cancers demonstrated the highest rate of annual growth in record count by comparison with other cancer types, while publications for gynecological cancers showed the slowest growth. The most common radiosensitizers investigated included ATM kinase inhibitors, chemotherapies, gold nanoparticles, mTOR inhibitors, natural compounds such as caffeine or curcumin, and poly (ADP-ribose) polymerase inhibitors. Conclusions: The United States, Germany, and China were the most productive countries during the study period, with China demonstrating the greatest increase in annual publication rate. Additionally, pre-clinical studies primarily investigated gold particles and targeted therapies. By comparison, clinical studies focused on radiosensitizing chemotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.